Clinical trials for Leukoencephalopathy with calcifications and cysts
50 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT0685282068Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)Melissa Lumish · PI: Melissa Lumish, MD
- RECRUITINGN/ANCT04996914Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular CarcinomaRWTH Aachen University · PI: Michael J. Eble, Professor Dr. med.
- RECRUITINGPhase 2NCT07219459Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 FailureCatalYm GmbH
- ACTIVE NOT RECRUITINGPhase 2NCT07380633Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative TrialSun Yat-sen University
- RECRUITINGNCT07432347Decoding Epigenetic Mechanisms Driving Immune Evasion in Liver Cancer With Omics ApproachesNiguarda Hospital · PI: Gianluca Mauri, MD
- RECRUITINGNCT07436845Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and ImmunotherapyNanfang Hospital, Southern Medical University
- RECRUITINGPhase 2NCT07274774SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular CarcinomaShandong Cancer Hospital and Institute
- RECRUITINGPhase 1NCT07275073JMT106 Injection in the Treatment of Advanced Solid TumorsShanghai JMT-Bio Inc.
- RECRUITINGN/ANCT06999837[68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling.Nantes University Hospital
- RECRUITINGPhase 3NCT06921785Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaAstraZeneca
- RECRUITINGNCT06950827Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular CarcinomaWest China Hospital
- RECRUITINGPhase 2NCT06860490HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)Fudan University
- RECRUITINGPhase 2NCT06742892A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard TherapyShanghai Henlius Biotech · PI: Hua Xiang, Dr.
- RECRUITINGN/ANCT06961526Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and BevacizumabTanta University · PI: Rania M Elkafoury, MD
- ENROLLING BY INVITATIONNCT06618300Streamlined Resin Y90 Radiation Segmentectomy for Small HCCUNC Lineberger Comprehensive Cancer Center · PI: Hyeon Yu, MD, FSIR
- RECRUITINGNCT06767579Comparison of the Incidence of Delirium Caused by Different Anesthetic Agents in Patients Undergoing Liver TransplantationYonsei University
- RECRUITINGN/ANCT06624098Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular CarcinomaSun Yat-sen University · PI: Feng Duan, MD
- RECRUITINGNCT06641713HAIC Compared With TACE in Huge Hepatocellular CarcinomaSun Yat-sen University · PI: Feng Duan, MD
- RECRUITINGPHASE1, PHASE2NCT06590246A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)Shanghai AbelZeta Ltd.
- RECRUITINGN/ANCT06581315Postoperative Adjuvant Therapy of Donafenib for Hepatocellular CarcinomaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · PI: Changzhen Shang, MD
- ENROLLING BY INVITATIONNCT06712017Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in ChinaGrandPharma (China) Co., Ltd. · PI: Xiaobin Feng, MD
- RECRUITINGNCT06561399Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)Fujian Provincial Hospital · PI: Shao-Ming Wei
- RECRUITINGPhase 2NCT06349980A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.Shanghai Henlius Biotech · PI: Jia Fan
- RECRUITINGPhase 2NCT06526338Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation AloneRobert C. Martin · PI: Robert CG Martin, MD, PhD
- RECRUITINGN/ANCT06061276bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCCSun Yat-sen University · PI: Zhimei Hunag, MD
- RECRUITINGPhase 2NCT06406634Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular CarcinomaHunan Cancer Hospital
- RECRUITINGPhase 2NCT06215651Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular CarcinomaPeking Union Medical College Hospital
- RECRUITINGPhase 1NCT06204835ITGA6 Targeting NIR-II Fluorescence Image Guided SurgeryInstitute of Automation, Chinese Academy of Sciences · PI: Zhenhua Hu, Ph. D
- ACTIVE NOT RECRUITINGN/ANCT05953337Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)ABK Biomedical · PI: Andrew Kennedy, MD
- RECRUITINGPHASE1, PHASE2NCT05797805A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular CarcinomaIterion Therapeutics
- RECRUITINGN/ANCT05984511TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTTThird Affiliated Hospital, Sun Yat-Sen University · PI: Mingsheng Huang, M.D. & Ph.D.
- RECRUITINGPhase 3NCT06172205Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCCSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- RECRUITINGN/ANCT05810402Liver Cancer and Immunotherapy in the Liquid Biopsy EraUniversity Hospital, Montpellier · PI: Catherine Alix-Panabières, Ph.D.
- RECRUITINGPhase 2NCT05844046Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) PatientsEnrico De Toni
- RECRUITINGPhase 3NCT05482516Evaluating Novel Therapies in ctDNA Positive GI CancersGeorgetown University · PI: John L. Marshall, MD
- ENROLLING BY INVITATIONNCT06540508Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and Prognosis of TACE Combined With Targeted Immunotherapy in Unresectable Hepatocellular CarcinomaCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGPhase 3NCT05613478Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular CarcinomaThe First Affiliated Hospital with Nanjing Medical University · PI: Xuehao Wang, professor
- RECRUITINGPhase 1NCT06044506Autologous Natural Killer Cell Therapy for Hepatocellular CarcinomaDr Cipto Mangunkusumo General Hospital · PI: Cosphiadi Irawan, MD, PhD
- RECRUITINGNCT05763277Ate-Bev Early Response Prediction Model in Advanced HCCSeoul National University Hospital
- RECRUITINGPhase 2NCT05412589mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCCSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · PI: linhui Peng, Prof
- ACTIVE NOT RECRUITINGPhase 3NCT05301842Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCCAstraZeneca
- RECRUITINGPhase 2NCT04430452Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular CarcinomaMary Feng, MD · PI: Mary Feng, MD
- RECRUITINGPhase 2NCT05057845Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular CarcinomaFudan University · PI: Peng Wang, MD
- RECRUITINGEarly Phase 1NCT05035108The Treatment of Bioartificial Liver With hiHep Cells After Extensive HepatectomySir Run Run Shaw Hospital · PI: Yifan Wang, MD
- ACTIVE NOT RECRUITINGPhase 3NCT04639180A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationJiangsu HengRui Medicine Co., Ltd.
- RECRUITINGPhase 3NCT04595864Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver TransplantationThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · PI: Beicheng Sun, PhD，MD
- ACTIVE NOT RECRUITINGPhase 3NCT04039607A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaBristol-Myers Squibb · PI: Bristol-Myers Squibb
- RECRUITINGPHASE1, PHASE2NCT03539822Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal MalignanciesAnwaar Saeed · PI: Anwaar Saeed, MD
- RECRUITINGNCT04190849European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)Cambridge University Hospitals NHS Foundation Trust · PI: David B Savage
- ACTIVE NOT RECRUITINGPhase 2NCT02221778SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACEUniversity of Sao Paulo · PI: Flair J Carrilho, MD, PhD